Unknown

Dataset Information

0

Discovery of Potent N-Ethylurea Pyrazole Derivatives as Dual Inhibitors of Trypanosoma brucei and Trypanosoma cruzi.

ABSTRACT: Trypanosoma brucei (T. brucei) and Trypanosoma cruzi (T. cruzi) are causative agents of parasitic diseases known as human African trypanosomiasis and Chagas disease, respectively. Together, these diseases affect 68 million people around the world. Current treatments are unsatisfactory, frequently associated with intolerable side-effects, and generally inadequate in treating all stages of disease. In this paper, we report the discovery of N-ethylurea pyrazoles that potently and selectively inhibit the viability of T. brucei and T. cruzi. Sharp and logical SAR led to the identification of 54 as the best compound, with an in vitro IC50 of 9 nM and 16 nM against T. b. brucei and T. cruzi, respectively. Compound 54 demonstrates favorable physicochemical properties and was efficacious in a murine model of Chagas disease, leading to undetectable parasitemia within 6 days when CYP metabolism was inhibited.

SUBMITTER: Varghese S 

PROVIDER: S-EPMC7073874 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Discovery of Potent <i>N</i>-Ethylurea Pyrazole Derivatives as Dual Inhibitors of <i>Trypanosoma brucei</i> and <i>Trypanosoma cruzi</i>.

Varghese Swapna S   Rahmani Raphaël R   Russell Stephanie S   Deora Girdhar Singh GS   Ferrins Lori L   Toynton Arthur A   Jones Amy A   Sykes Melissa M   Kessler Albane A   Eufrásio Amanda A   Cordeiro Artur Torres AT   Sherman Julian J   Rodriguez Ana A   Avery Vicky M VM   Piggott Matthew J MJ   Baell Jonathan B JB  

ACS medicinal chemistry letters 20190909 3

<i>Trypanosoma brucei</i> (<i>T. brucei</i>) and <i>Trypanosoma cruzi</i> (<i>T. cruzi</i>) are causative agents of parasitic diseases known as human African trypanosomiasis and Chagas disease, respectively. Together, these diseases affect 68 million people around the world. Current treatments are unsatisfactory, frequently associated with intolerable side-effects, and generally inadequate in treating all stages of disease. In this paper, we report the discovery of <i>N</i>-ethylurea pyrazoles t  ...[more]

Similar Datasets

Unknown Discovery of potent and selective inhibitors of Trypanosoma brucei ornithine decarboxylase.
| S-EPMC2878083 | biostudies-literature
Unknown Discovery of N-(2-aminoethyl)-N-benzyloxyphenyl benzamides: New potent Trypanosoma brucei inhibitors.
| S-EPMC5419589 | biostudies-literature
Unknown Effects of camptothecin derivatives and topoisomerase dual inhibitors on Trypanosoma cruzi growth and ultrastructure.
| S-EPMC4066697 | biostudies-literature
Unknown Indirubin derivatives are potent and selective anti-Trypanosoma cruzi agents.
| S-EPMC7000199 | biostudies-literature
Unknown Non-natural acetogenin analogues as potent Trypanosoma brucei inhibitors.
| S-EPMC4298241 | biostudies-literature
Unknown Structure-guided discovery of selective methionyl-tRNA synthetase inhibitors with potent activity against <i>Trypanosoma brucei</i>.
| S-EPMC7649832 | biostudies-literature
Unknown Discovery of Indoline-2-carboxamide Derivatives as a New Class of Brain-Penetrant Inhibitors of Trypanosoma brucei.
| S-EPMC4601051 | biostudies-literature
Unknown Aryloxyethyl Thiocyanates Are Potent Growth Inhibitors of Trypanosoma cruzi and Toxoplasma gondii.
| S-EPMC4447534 | biostudies-literature
Unknown Sugar nucleotide pools of Trypanosoma brucei, Trypanosoma cruzi, and Leishmania major.
| S-EPMC1951125 | biostudies-literature
Unknown Development of Simplified Heterocyclic Acetogenin Analogues as Potent and Selective Trypanosoma brucei Inhibitors.
| S-EPMC5111590 | biostudies-literature